Apalutamide-induced severe interstitial lung disease: A report of two cases from Japan
| Autor: | Keisuke Tomii, Hiroki Hagimoto, Hiroshi Kobe, Ryo Tachikawa, Yoshitsugu Masuno, Shiori Murata, Atsushi Matsunashi |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
Pulmonary and Respiratory Medicine medicine.medical_specialty Pulmonary toxicity Antineoplastic Agents Gastroenterology 03 medical and health sciences Prostate cancer chemistry.chemical_compound 0302 clinical medicine Japan Internal medicine Humans Medicine 030212 general & internal medicine business.industry Apalutamide Interstitial lung disease medicine.disease Clinical trial Androgen receptor Prostatic Neoplasms Castration-Resistant Thiohydantoins 030228 respiratory system Respiratory failure chemistry Methylprednisolone Lung Diseases Interstitial business medicine.drug |
| Zdroj: | Respiratory Investigation. 59:700-705 |
| ISSN: | 2212-5345 |
| Popis: | Apalutamide, a competitive inhibitor of the androgen receptor, is being increasingly used for the treatment of prostate cancer. There have been few reports of interstitial lung disease in clinical trials of apalutamide. However, two cases of apalutamide-induced interstitial lung disease with respiratory failure in Japanese males, who were successfully treated with high-dose corticosteroids, are presented here. These cases suggest that clinicians should be alert to the potentially life-threatening risk of pulmonary toxicity associated with apalutamide treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect